On the evening of January 25, 2024, Blue Sail Medical (002382.SZ) announced that its wholly-owned subsidiary, Beijing Blue Sail Biosensors Medical Technology Co., Ltd. (hereinafter referred to as "Blue Sail Biosensors"), the main business entity for cardiovascular and cerebrovascular diseases, plans to introduce strategic investors including Capital Health Industry (Beijing) Fund (Limited Partnership), Hebei Lingkong Private Equity Fund, and Linqu High Tech Industrial Investment for a capital increase and expansion. The investors will inject a total of RMB 900 million in cash into Blue Sail Biosensors.

CEC Capital served as the exclusive financial advisor to Blue Sail Biosensors in this transaction. This deal marks the largest private equity financing transaction in the Chinese medical device industry in the past two years.

As the holding platform for the cardiovascular and cerebrovascular business unit of Blue Sail Medical, Blue Sail Biosensors was created through the integration of Singapore Biosensors International Group (including China Jiwei Medical), Germany NVT, Blue Sail Shanghai Research and Development Center, and other entities. With a globally distributed R&D management team composed of top talents from both domestic and overseas, Blue Sail Biosensors has been expanding its global footprint, broadening its product range, and enhancing localization efforts in China. Its products on sale cover coronary implantation, valve replacement and repair systems, and agency products, including Xinyue?, Xinkuo?, Xinxun?, BioFreedom?, Allegra?, etc. Among them, BioFreedom? is recognized as the global "gold standard" product in the field of high bleeding risk patients (HBR).

The capital increase consists of various forms of ownership, including state-owned capital and private capital. The introduction of strategic investors through this capital increase has optimized the shareholding structure of Blue Sail Biosensors. Leveraging the advantages of industrial funds in the healthcare sector and state-owned investment platforms, Blue Sail Biosensors can access high-quality industrial resources and create synergies between capital and the industry chain. Additionally, this capital increase, combined with Blue Sail Biosensors' own development needs and capital operation planning, will help provide necessary funds for business development and accelerate its expansion in the high-end innovative medical device market, aligning with the long-term strategic development goals of both Blue Sail Medical and Blue Sail Biosensors.